Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.38 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 704,919 shares traded.
Several analysts recently commented on the stock. Ascendiant Capital Markets increased their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a research note on Wednesday, September 11th. StockNews.com raised Atossa Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $6.00 target price on shares of Atossa Therapeutics in a research report on Thursday, October 31st.
View Our Latest Analysis on ATOS
The stock's fifty day moving average price is $1.43 and its 200-day moving average price is $1.38. The firm has a market cap of $188.64 million, a price-to-earnings ratio of -7.14 and a beta of 1.23.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. As a group, equities research analysts predict that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in Atossa Therapeutics in the second quarter valued at about $29,000. Cetera Advisors LLC bought a new stake in shares of Atossa Therapeutics in the 1st quarter valued at approximately $72,000. SG Americas Securities LLC increased its holdings in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock worth $64,000 after buying an additional 30,037 shares during the last quarter. Virtu Financial LLC bought a new position in Atossa Therapeutics during the first quarter valued at approximately $151,000. Finally, Rhumbline Advisers acquired a new stake in Atossa Therapeutics in the second quarter valued at approximately $161,000. Hedge funds and other institutional investors own 12.74% of the company's stock.
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.